WuXi AppTec Co Ltd
WuXi AppTec Co Ltd operates as a pharmaceutical services provider within the Healthcare sector, generating revenue through life sciences tools and services activities.
Business. WuXi AppTec Co Ltd (2359.HK) is a healthcare company operating in the pharmaceuticals and medical research industry. The firm is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the pharmaceutical sector.
Analyst recommendations
20 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
2Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
WuXi AppTec Co Ltd (2359.HK) is a healthcare company operating in the pharmaceuticals and medical research industry. The firm is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the pharmaceutical sector.
WuXi AppTec maintains a conservative capital structure with a debt-to-equity ratio of 0.11 and a current ratio of 3.21, indicating strong short-term liquidity coverage. The balance sheet shows total assets of 103.1 billion CNY against total liabilities of 23.4 billion CNY, resulting in total equity of 79.7 billion CNY. Despite the strong current ratio, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting reliance on operating cash flow to service obligations. The company generated 16.4 billion CNY in operating cash flow and 11.1 billion CNY in free cash flow, supporting its capital expenditure of 5.5 billion CNY.
Profitability metrics are robust, with a return on equity of 24.08% and a return on assets of 18.61%. The company reports a net income of 19.2 billion CNY on revenue of 43.4 billion CNY, yielding a net margin of approximately 44.2%. Operating income stands at 21.8 billion CNY, indicating high operational leverage. These returns suggest efficient capital deployment relative to the asset base, although specific cohort median comparisons are not provided in the input data to benchmark against industry peers.
- WuXi AppTec trades at a compressed P/E of 3.96 and EV/EBITDA of 3.88, reflecting a low valuation relative to its earnings power.
- Strong profitability is evidenced by a 24.08% ROE and 18.61% ROA, driven by high net margins on 43.4 billion CNY in revenue.
- Liquidity is supported by a 3.21 current ratio and 11.1 billion CNY in free cash flow, though net cash is negative after debt.
- Dilution risk is low with no difference between basic and diluted share counts, preserving existing shareholder value.
- Analyst sentiment is positive with a mean recommendation of 1.70 and a median price target of 169.80 CNY, implying upside from current levels.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 6,20 |
| Revenue | —no estimate | —no estimate | 53,1B CNY |
| Operating income | —no estimate | —no estimate | 21,3B CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Return On Assetsnet_income / total_assets
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- WuXi AppTec Co Ltd Market data — financials · 2026-07-11
- WuXi AppTec Co Ltd Market data — analyst estimates · 2026-07-11
- WuXi AppTec Co Ltd Market data — ESG · 2026-07-11
- WuXi AppTec Co Ltd — company reference export (2026-07-05) · 2026-07-11